STAT3 and lung carcinoma: In lung cancer, AKR1B1 is a STAT3 activator that promotes glutathione de novo synthesis, eliminates ROS, protects cell from death, and reduces EGFR TKI drug sensitivity by upregulating the cystine transporter SLC7A11, it would be a therapeutic target for dealing with EGFR TKI resistance (50).